Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.70, $0.52 better than the analyst estimate of $1.18. Revenue for the quarter came in at $59.6 million versus the consensus estimate of $51.26 million.

GUIDANCE:

Ligand Pharma sees FY2019 EPS of $6.05, up from $5.50 and versus the consensus of $6.60. Ligand Pharma sees FY2019 revenue of $224 million, up from $212 million and versus the consensus of $243.3 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.